Advik Laboratories Ltd

AGM details

• AGM held on 29 Sep 2026 at 9:30 AM
• Mode: Physical with remote e-voting
• Remote e-voting closed on 28 Sep 2026 at 5:00 PM

Resolutions put to vote

• Ordinary: Adoption of audited financial statements for year ended 31 March 2026
• Ordinary: Re-appointment of Ram Niwas Sharma by rotation
• Special: Re-appointment of Nemani Garg Agarwal & Co. as statutory auditors
• Ordinary: Approval for related party transactions under section 188 and SEBI LODR
• Special: Appointment of Anchal Goyal as Independent Director
• Special: Approval of transactions under section 185 of the Companies Act 2013

Voting results

• Results and Scrutinizer report to be intimated to exchanges and placed on the company site within 2 working days

Directors and auditors

• Anchal Goyal appointed as Independent Director
• Ram Niwas Sharma to retire by rotation and be eligible for re-appointment
• Nemani Garg Agarwal & Co. re-appointed as Statutory Auditors
• Scrutinizer for remote e-voting: Kundan Agarwal & Associates

Related party and other approvals

• Approval for Related Party Transactions under section 188
• Approval for transactions under section 185 of the Companies Act 2013

MPS Pharmaa Limited (Formerly Advik Laboratories Limited) — Closure of trading window from Thursday, 01st October, 2026 upto 48 hours after the Unaudited Financial Results of the Company for the quarter & half year ending 30th September, 2026 are declared to the Stock Exchange and made public

Trading window of MPS Pharmaa Limited (Formerly Advik Laboratories Limited) closes from 01 October 2026 up to 48 hours after the unaudited financial results for the quarter ending 30 September 2026 are declared to the stock exchange and made public.

Book Closure Details

• Book closure: 23 Sep 2026 to 29 Sep 2026 (inclusive) for the AGM.
• Purpose: ensuing Annual General Meeting.

AGM timing and notices

• Approved 29 September 2026 at 9:30 AM for the 32nd AGM.
• Approved AGM notice, Directors' Report, MD&A, and Corporate Governance Report.
• Book closure from 23 September to 29 September 2026.
• NSDL appointed as depository for e-voting.
• E-voting window from 26 September 2026 to 28 September 2026.
• Scrutinizer appointed: M/s. Kundan Agrawal & Associates.

Appointments and approvals proposed

• Proposed appointment of Ms Anchal Goyal as Independent Director for 5 years.
• Proposed reappointment of Nemani Garg Agarwal & Co. as Statutory Auditors for 5 years.
• Authorization under Section 185 of the Companies Act 2013 for shareholder approval.

Regulatory disclosures

• Details and terms annexed as per SEBI Circular CIR/CFD/CMD/4/2015.
• Annexures A and B attached detailing appointment terms.

Meeting Details

• Date, time, venue: 02 Sep 2026, 3:00 PM, at 703, Arunachal Building, 19, Barakhambha Road, New Delhi-110001.

Key Agenda Items

• To consider and approve the AGM notice for FY 2025-26.
• To approve Director’s Report, MD&A and Corporate Governance Report for FY 2025-26.
• To fix date, time and venue of the forthcoming AGM for FY 2025-26.
• To appoint a Scrutinizer for the forthcoming AGM.
• To fix book-closure and E-voting dates and related matters.
• To consider any other matter with the permission of the Board.

Other Notes

• Company renamed as MPS Pharmaa Limited from Advik Laboratories Limited.

Financial results approved

• Standalone unaudited results for quarter ended 30 June 2026 approved.
• Limited Review Report on the standalone results approved.

Regulatory filings and outlook

• FDA licence renewal for drug manufacturing applied; under consideration.
• Management expects restart; pursuing market opportunities and new deal prospects.

Auditor remarks and emphasis

• Auditors' review notes no revenue from operations in quarter ended June 2026.
• Basis of qualified conclusion: investment fair value not determined; WIP stalled.

Market and regulatory actions

• BSE trading suspended for unpaid listing fees; weekly Trade-for-Trade allowed.
• March 31, 2026 figures are balancing figures.

Meeting Details

• Date and time: 13 August 2026 at 12:00 PM.
• Venue: 703, Arunachal Building, 19 Barakhamba Road, Connaught Place, New Delhi-110001.

Key Agenda Items

• Consider and approve unaudited financial results for quarter ended 30 June 2026 and the Limited Review Report.

Other Notes

• Trading window closed for unaudited Q1 FY2026 results; remains closed till 15 August 2026.